Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralipid effect on NK cells in recurrent miscarriage
NCT03132779Phase 1Unknown
- Start
- May 2017
- Primary completion
- Jan 2018
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of Intralipid 10% in recurrent miscarriage (RPL). Primary endpoint: Change in NK cells activity after injection of intralipid at 1 week. Status: unknown.
02
Drugs
Intralipid 10%
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on NCT03132779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132779.